# Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

> **NCT05102747** · NA · RECRUITING · sponsor: **Centre Francois Baclesse** · enrollment: 504 (estimated)

## Conditions studied

- Brain Metastasis
- Oligoprogression

## Interventions

- **RADIATION:** Hypofractionated SRT (stereotactic radiotherapy)
- **RADIATION:** Historical single-dose SRS (stereotactic radiosurgery)

## Key facts

- **NCT ID:** NCT05102747
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2030-01
- **Final completion:** 2031-01
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102747, "Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05102747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*